{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Hampel H"],"funding":["European Research Council","NIA NIH HHS","Medical Research Council","NINDS NIH HHS"],"pagination":["130"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7566058"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(1)"],"pubmed_abstract":["β-Secretase1 (BACE1) protein concentrations and rates of enzyme activity, analyzed in human bodily fluids, are promising candidate biological markers for guidance in clinical trials investigating BACE1 inhibitors to halt or delay the dysregulation of the amyloid-β pathway in Alzheimer's disease (AD). A robust body of evidence demonstrates an association between cerebrospinal fluid/blood BACE1 biomarkers and core pathophysiological mechanisms of AD, such as brain protein misfolding and aggregration, neurodegeneration, and synaptic dysfunction.In pharmacological trials, BACE1 candidate biomarkers may be applied to a wide set of contexts of use (CoU), including proof of mechanism, dose-finding, response and toxicity dose estimation. For clinical CoU, BACE1 biomarkers show good performance for"],"journal":["Alzheimer's research & therapy"],"pubmed_title":["β-Secretase1 biological markers for Alzheimer's disease: state-of-art of validation and qualification."],"pmcid":["PMC7566058"],"funding_grant_id":["G0801418","1499398","RF1 AG046929","UKDRI-3003","MR/P005748/1","1947196","MR/T04604X/1","MR/L023784/2","720931","G0801418B","681712","MR/L010305/1","RF1 NS074256"],"pubmed_authors":["Caraci F","Corbo M","Saidi A","Nistico R","Zugaza JL","Vellas B","Giorgi FS","Garaci F","Hanisch B","Bonuccelli U","Zetterberg H","Rossi S","Villain N","Cummings JL","Geerts H","Toschi N","Castrillo J","Hernandez F","Galgani A","Kim SH","Koronyo-Hamaoui M","Kapogiannis D","Ritchie C","Herholz K","Valenzuela PL","Palermo G","Black KL","Dubois B","Babiloni C","Caruso G","Mapstone M","Lemercier P","Benda N","Habert MO","Lehericy S","Neri C","Batrla R","Goetzl EJ","Imbimbo BP","Emanuele E","Corvol JC","Duggento A","Lucia A","Ferretti MT","Kiddle SJ","Blennow K","Depypere H","Frank RA","Watling M","Vanmechelen E","Mango D","Escott-Price V","Lista S","Sporns O","Bokde ALW","Younesi E","Alzheimer’s Precision Medicine Initiative (APMI)","Fiandaca M","Avila J","Cavedo E","Santarnecchi E","Graziani M","Arenas J","Cuello AC","Virecoulon Giudici K","Hampel H","Cacciola F","Welikovitch LA","Perry G","Verdooner SR","Schneider LS","Woodcock J","Haberkamp M","Yan R","Aguilar LF","Giacobini E","Vergallo A","Broich K","Chiesa PA","Langevin T","Federoff H","Akman-Anderson L","Das B","Afshar M","O'Bryant SE","Baldacci F","Karran E","Ceravolo R","Koronyo Y","Llavero F","Lorenceau J"],"additional_accession":[]},"is_claimable":false,"name":"β-Secretase1 biological markers for Alzheimer's disease: state-of-art of validation and qualification.","description":"β-Secretase1 (BACE1) protein concentrations and rates of enzyme activity, analyzed in human bodily fluids, are promising candidate biological markers for guidance in clinical trials investigating BACE1 inhibitors to halt or delay the dysregulation of the amyloid-β pathway in Alzheimer's disease (AD). A robust body of evidence demonstrates an association between cerebrospinal fluid/blood BACE1 biomarkers and core pathophysiological mechanisms of AD, such as brain protein misfolding and aggregration, neurodegeneration, and synaptic dysfunction.In pharmacological trials, BACE1 candidate biomarkers may be applied to a wide set of contexts of use (CoU), including proof of mechanism, dose-finding, response and toxicity dose estimation. For clinical CoU, BACE1 biomarkers show good performance for","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Oct","modification":"2025-06-01T04:10:12.511Z","creation":"2020-10-29T12:40:29Z"},"accession":"S-EPMC7566058","cross_references":{"pubmed":["33066807"],"doi":["10.1186/s13195-020-00686-3"]}}